Clinical trial NCT05055518: APL-102 Capsule in Patients With Advanced Solid Tumors
Official title: Phase I Study on Safety, Tolerance, and Pharmacokinetics of APL-102 Capsule in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Solid Tumor
Lead sponsor: Apollomics Inc.
Sponsor class: INDUSTRY
Collaborators: name: Zhejiang CrownMab Biotech Co. Ltd
First posted: 2021-09-24
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Subjects will be assigned to a dose level of APL-102 in the order of study entry. A total of seven therapeutic dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned. To reduce the number of subjects exposed to potentially ineffective doses and protect the rights and interests of subjects, rapid titration was used in the low-dose group (1 mg, 2 mg, 3 mg); When approaching the expected effective dose of 5 mg, the "3 + 3" study design was used.
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.

Detailed description: This study is an open, multicenter dose-escalation study to evaluate the safety and tolerance of APL-102 and obtain the relevant data of APL-102 in patients with advanced solid tumors. In the dose escalation stage, based on the incidence of dose limited toxicity (DLT) and adverse event (AE), explore and determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D). After RP2D and administration protocol are determined, an extended study will be conducted on 6-10 subjects to further evaluate the safety and antitumor activity of APL-102.

Eligibility criteria: Major Inclusion Criteria:

1. Male or female, age ≥ 18 and ≤ 75 years old.
2. Patients with unresectable or metastatic advanced solid tumors confirmed by histology or cytology, and after the failure of standard treatment, or cannot tolerate standard treatment, or have no standard treatment.
3. There were measurable lesions according to the efficacy evaluation criteria of solid tumors (RECIST version 1.1).
4. Eastern Cooperative Oncology Group(ECOG) performance status score is 0 to 1.
5. Life expectancy is more than 3 months after the first administration.
6. The organ function level must meet the following requirements:

   Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.0× upper limit of normal value (ULN) (patients with liver metastasis≤ 5 × ULN). Serum bilirubin ≤ 1.5×ULN (total bilirubin ≤ 3×ULN in patients with Gilbert syndrome). Absolute neutrophil count ≥ 1.5×10\^9/L. Platelet count ≥ 100×10\^9/ L. Hemoglobin ≥ 9 g / dL.
7. No other chemotherapy was received within four weeks before the first administration of the trial; All previous anti-tumor treatments, including targeted therapy and endocrine therapy, shall pass through at least five half-lives (or no more than 28 days) after receiving targeted therapy/endocrine therapy, and patient shall recover to the standard level specified in the test from the toxic reaction of the treatment.
8. For patients who have received radiotherapy for spine and/or peripheral limbs, they can only be enrolled after four weeks and two weeks before the first administration and should recover from the toxic reaction of treatment to the standard level specified in the study.
9. No major surgery was performed within four weeks before the first administration of APL-102., etc.

Major Exclusion Criteria:

1. Previous treatment with VEGF(vascular endothelial growth factor)/ VEGFR(vascular endothelial growth factor receptor) inhibitors (except bevacizumab for colorectal cancer).
2. In addition to the malignancies in the study, patients with systemic diseases leading to poor medical risk (such as uncontrollable infection in the active phase).
3. Life-threatening diseases, severe organ dysfunction, interference with the absorption or metabolism of APL-102, or other reasons that the researchers believe may endanger the safety of subjects or affect the integrity of research results.
4. Patients with a history of heart disease or potential risk of heart disease.
5. Patients with low circulatory function as defined by the New York Heart Association's (NYHA) functional criteria.
6. Patients with a definite diagnosis of chronic obstructive pulmonary disease, bronchial asthma or interstitial lung disease, or patients with forced expiratory volume in one second/ forced vital capacity (FEV1/FVC) ratio \< 80% in pulmonary function test.
7. Patients with decompensated cirrhosis or history of allogeneic bone marrow transplantation or organ transplantation.
8. Patients in repeated resting states during screening had mean systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or positive proteinuria (allowing antihypertensive agents to control blood pressure).
9. Patients requiring antiplatelet/anticoagulant therapy (including but not limited to aspirin or low molecular weight heparin sodium and warfarin).
10. Have a history of human immunodeficiency virus (HIV) infection or HIV antibody positive; or seropositive results consistent with active infection for hepatitis B virus (in case of only hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive, the examination of Hepatitis B (HBV) DNA copy number is needed) or hepatitis C virus.
11. Patients with the symptomatic primary brain tumor and/or secondary brain metastasis, uncontrollable antiepileptic drugs and requiring high-dose steroid treatment. Or cerebrovascular accident, transient ischemic attack, or intermittent claudication within six months before treatment.
12. Patients who need to be treated with drugs metabolized through Cytochrome P450 (CYP450) system, especially those who need to be treated with drugs metabolized through Cytochrome p450 3A4( CYP3A4).
13. Pregnant or lactating patients., etc.

Primary outcomes:
measure: DLT
timeFrame: 36 days
measure: Adverse Events (AEs)
timeFrame: From time of informed consent signature to 30 days after the subject's last visit (approximately 1 year)
Secondary outcomes:
measure: Incidence of Adverse Events
timeFrame: From time of informed consent signature to 30 days after the subject's last visit (approximately 1 year)
measure: Objective response rate(ORR)
timeFrame: Approximately 1 year
measure: Duration of response(DOR)
timeFrame: Approximately 1 year
measure: Progression-free survival(PFS)
timeFrame: Approximately 1 year
measure: Overall survival(OS)
timeFrame: Approximately 1 year
measure: Peak plasma concentration (Cmax)
timeFrame: 36 days
measure: Time to reach Cmax (Tmax)
timeFrame: 36 days
measure: The area under the plasma concentration-time curve from time zero to the last measurable time point (AUC0-t)
timeFrame: 36 days
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study officials:
affiliation: Investigator
name: Yihebali Chi, PhD
role: PRINCIPAL_INVESTIGATOR
References: